**[265] AUTOMATING THE EVALUATION OF "ULTRASOUND OF THE HEART" ("ECHO")**

**Hila Goldman-Aslan0, Noah Liel-Cohen1, 1 Soroka University Medical Center in Beer-Sheva, Israel**

**Dia Cardio Ltd.**

* **Investment Rational**   
  DiACardio’s is a software company that invented new image processing technology that automates the evaluation of “Ultrasound of the Heart”, thereby dramatically improving the speed and accuracy with which evaluation can be reached. The software achieved FDA and CE approval, and sales have been secured in the US. The management team includes medical & image processing key opinion leaders and experience business team players.
* **Business Strategy**

  2. Out technology can be easily integrated as part of the ultrasound device or the healthcare IT (PACS) systems. Our business model is OEM where the ultrasound or healthcare IT Companies pays onetime fee (per device, site…) and maintenance. We already generate initial revenues and expect to increase revenues by developing and releasing more automated tools needed in the medical imaging market.
* **Core Technology**   
  Based on new image processing technology that we invented, we created sophisticated algorithms that for the first time enable to track the heart borders and find the main parameters of the heart- automatically, with one click, in just few seconds. Our ability to run on low memory and processing power devices is another significant advantage we have over competitors.
* **Product Profile/Pipeline**   
  Our first tool LVivo EF is FDA and CE certified and has OEM customers in the US. We are commercial stage with others, including Strategic partners. And more automated tools are on the way. By the end of 2016 we will have a prototype of the "UltraScope" low cost mobile cardio ultrasound with our automated tools, for use at Point of Care (GP’s, medics, nurses…)
* **What's Next?**   
  We intend to close an A round of investment during 2016 and by than we expect to release more automated tools for the heart that need automation and conduct clinical trials on new tools. We plan to expand our R&D team and M&S team in order to accelerate our R&D plans, market penetration and closing additional OEM deals.